ArriVent BioPharma Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for ArriVent BioPharma, Inc. (AVBP) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021
Period EndingDec 2024Dec 2023Dec 2022Dec 2021
Operating Activities
Net Income-80.49-69.33-36.91-68.81
Stock Based Compensation3.210.900.420.07
Change in Working Capital7.0712.60-7.15-5.25
Change in Accounts Payable-0.751.382.800.39
Change in Other Working Capital7.8211.22-9.95-5.65
Net Cash from Operating Activities-70.21-55.84-43.63-16.78
Investing Activities
Purchases of Investments-192.47-25.000.000.00
Sales/Maturities of Investments1.7025.000.00-53.33
Net Cash from Investing Activities-192.470.000.00-53.33
Financing Activities
Debt Repayment0.000.000.00-0.27
Common Stock Issued186.580.350.000.00
Other Financing Activities0.63-2.410.000.00
Net Cash from Financing Activities186.5842.86169.72119.82
Summary
Net Change in Cash-76.10-12.98126.0949.71
Cash at Beginning of Period150.39163.3737.280.00
Cash at End of Period74.29150.39163.370.00
Free Cash Flow-70.21-55.84-43.630.00